How to Choose a CDMO for Biologics

The short answer: Choosing a CDMO for biologics is decided by three things, in order: platform and expression-system fit (does the partner run your cell line — typically CHO for a monoclonal antibody, or microbial for a simpler protein — as a proven process, not a first attempt); analytical characterization depth (can they actually measure glycosylation, aggregation, charge variants and the rest of the quality attributes a biologic lives or dies on, and support a comparability exercise); and demonstrated regulatory experience with your modality through a BLA or equivalent. Bioreactor capacity and single-use vs stainless matter, but they are the second question. Screen all of it against a clean GMP and inspection record, because for a sterile biologic the compliance bar is high.

Biologics are unforgiving to source badly. A small molecule is defined by its structure; a biologic is defined by its process — change the process and you can change the product. That makes the CDMO choice a decision about scientific and analytical capability far more than about a plant, and it makes a mid-program change of partner genuinely risky. This guide covers how to select for monoclonal antibodies and recombinant proteins. (For antibody-drug conjugates, which add a highly potent payload and a three-part supply chain, see choosing a CDMO for ADCs.)

What biologics manufacturing actually requires

Before evaluating vendors, be clear which stages you are buying, because few CDMOs are equally strong across all of them:

• Cell-line and upstream development — expression system, clone selection, and the fed-batch or perfusion cell-culture process that makes the molecule.
• Downstream purification — the chromatography and filtration train that isolates it to the required purity, and the impurity clearance you must demonstrate.
• Drug-substance to drug-product — formulation, and aseptic fill–finish of a sterile injectable, often with lyophilisation.
• Analytical characterization and release — the extensive panel that defines the product's critical quality attributes.

A CDMO that is strong upstream is not automatically strong at analytics or sterile fill–finish. Decide whether you want a single drug-substance-through-drug-product partner (fewer transfers) or best-of-breed specialists (deeper capability, more interfaces) before you shortlist.

1. Match the platform and expression system

Start from your molecule's platform:

• A monoclonal antibody almost always means mammalian (CHO) cell culture. Confirm the CDMO runs a proven, productive CHO platform — a defined host cell line, media, and process they have taken to licensure — rather than adapting yours from scratch.
• A simpler recombinant protein may use a microbial system (E. coli, yeast), which is a different facility, skill set, and downstream problem.
• Titer and productivity on a comparable molecule tell you more about real capability than nominal bioreactor volume.

A partner using their own well-characterised platform gives you speed and a lower comparability risk; adapting to an unfamiliar system adds both time and uncertainty.

2. Weight analytical characterization heavily

This is the axis buyers most often under-value. A biologic's identity, safety and efficacy are defined by attributes you can only see analytically. Confirm the CDMO can characterise and control:

• Glycosylation and other post-translational modifications,
• Aggregation and fragmentation, charge and size variants,
• Host-cell protein and DNA clearance,
• and can run the comparability studies you will need whenever the process changes — including the transfer to them.

Thin analytics is the biologics equivalent of a formulation you cannot measure: it surfaces as a problem exactly when the stakes are highest, at scale-up or in the regulatory review. The same "measure it or you cannot file it" principle applies as in formulation development.

3. Confirm capacity, technology, and scale fit

Now the plant questions — but framed by your program:

• Single-use vs stainless steel. Single-use suits clinical and mid-scale flexibility and speeds changeover; stainless steel suits large commercial volumes. Match to your projected demand, not the vendor's installed base.
• Scale headroom for your commercial forecast, so you are not forced into a disruptive transfer at launch.
• A credible drug-substance-to-drug-product path, in-house or via a clean technology transfer, so the sterile step is planned rather than improvised.

4. Require modality-specific regulatory experience

Biologics carry their own regulatory weight — a Biologics License Application (or the EU/UK equivalent), comparability expectations, and often a dedicated pre-licence inspection. Ask for evidence the CDMO has:

• taken a comparable modality through licensure,
• passed regulatory inspections of the relevant site, and
• can own the CMC/quality narrative for a biologic, not just execute a process.

Verify the specific site's inspection history the same way you would any supplier — its FDA Form 483, Warning Letter and recall record, read as a pattern.

Biologics-specific pitfalls

• Buying bioreactor volume instead of process fit. Capacity does not make your molecule; a proven platform and downstream train do.
• Under-scoping analytics, then discovering at scale-up that a critical attribute cannot be characterised or controlled.
• Treating drug substance and drug product as one problem when the sterile fill–finish and cold-chain requirements are a distinct, high-compliance discipline.
• Ignoring comparability risk in the transfer itself — moving a biologic between processes is where products quietly change.

Where this fits

Biologics selection runs on the same axes as any CDMO selection — capability fit, analytical rigour, GMP status, and inspection record — but weighted toward process and analytical depth because the process defines the product. If you are still deciding between development capability and pure manufacturing capacity, start with CRO vs CDMO vs CMO.

PharmaTek links CDMO capabilities to each company's GMP and FDA compliance record across a directory of 22,000+ pharmaceutical companies and manufacturers, so a biologics shortlist can be built for capability and screened for compliance at once.

Frequently asked questions

What is the most important factor when choosing a biologics CDMO? Process and platform fit. A biologic is defined by its manufacturing process, so the priority is a CDMO that runs your expression system (typically CHO for a monoclonal antibody, microbial for simpler proteins) as a proven, licensed platform — closely followed by the analytical depth to characterise and control the product's critical quality attributes. Bioreactor capacity is the second question, not the first.

Why does analytical characterization matter so much for biologics? Because a biologic's identity, safety and efficacy live in attributes — glycosylation, aggregation, charge and size variants, host-cell impurity clearance — that are only visible analytically. A CDMO without deep characterization and comparability capability cannot prove the product is what it should be, and the gap surfaces at scale-up or regulatory review, when it is most expensive to fix.

Should biologics drug substance and drug product be at the same CDMO? A single drug-substance-through-drug-product partner reduces technology transfers and comparability risk. Using specialists for each can give deeper capability but adds interfaces and a transfer to manage. Decide deliberately based on your molecule's complexity and your tolerance for hand-offs; the sterile fill–finish step in particular is a distinct, high-compliance discipline.

Single-use or stainless-steel bioreactors — which is better? Neither is universally better. Single-use systems suit clinical and mid-scale production and flexible, fast changeover; stainless steel suits large commercial volumes. Match the choice to your projected commercial demand rather than to the CDMO's installed base, and make sure there is scale headroom so you are not forced into a disruptive transfer at launch.

What regulatory experience should a biologics CDMO have? Evidence of taking a comparable modality through a Biologics License Application (or EU/UK equivalent), a clean inspection history at the specific manufacturing site, and the ability to own the CMC and comparability narrative — not just execute a process. Confirm the site's FDA Form 483, Warning Letter and recall record before contracting.

---

Building a biologics CDMO shortlist? Explore the supplier directory or book a demo to screen candidates against live GMP and FDA compliance data.